A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)

计划入组 795 人 · 首次发布于 2022 年 12 月 22 日

A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

计划入组 692 人 · 首次发布于 2022 年 7 月 19 日

A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin

计划入组 986 人 · 首次发布于 2022 年 3 月 11 日

Insulin efsitora alfa

ALPHA-0602

Alpha-101

Alpha Metallurgical

United States

Zeno Alpha, Inc.

United States

Alpha Republic GmbH

Austria

Landmark Clinical Trials of 2024: Advancements in Cancer, Metabolic Diseases, and Infectious Diseases

Lilly's Once-Weekly Insulin Efsitora Shows Promise in Phase 3 Diabetes Trials

Eli Lilly's Weekly Insulin Efsitora Shows Promise in Phase 3 Trials